A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)

Published:2008-05-20 Issue:15_suppl Volume:26 Page:7004-7004
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Verstovsek S.,Kantarjian H. M.,Pardanani A.,Thomas D. A.,Cortes J. E.,Mesa R.,Hogan W.,Redman J.,Levy R.,Vaddi K.,Tefferi A.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2008.26.15_suppl.7004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma;Cancers;2021-10-30

2. Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal;PharmacoEconomics;2013-08-31

3. The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL;New Agents for the Treatment of Acute Lymphoblastic Leukemia;2011

4. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms;Blood;2010-06-24

5. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis;Blood;2010-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP